Efficacy and prognosis of osimertinib plus pemetrexed/platinum in non small cell lung cancer with EGFR and TP53 mutations
WANG Wei
ZHOU Wei
Abstract：Objective To explore the efficacy and prognostic analysis of osimertinib combined with pemetrexed/platinum in non-small cell lung cancer(NSCLC)with EGFR and TP53 mutations.Methods Eighty patients with NSCLC with EGFR and TP53 mutations,who were diagnosed in 904th Hospital of Joint Logistics Support Force between January 2016 and June 2022,were randomly selected for this study.They were randomly divided into a control(40 patients)group and a study(40 patients)group.The control group received Osimertinib treatment,while the study group received pemetrexed/platinum combined with osimertinib treatment.The clinical efficacy,serum indicator levels,medication safety,and prognosis of the two groups were compared.Results The overall response rate(ORR)and disease control rate(DCR)of the study group were significantly better than those of the control group(P＜0.05).After treatment,the levels of cytokeratin 19 fragment(CYFRA21-1),and carcinoembryonic antigen(CEA)were significantly lower in both groups than before treatment(P＜0.05),and they were significantly lower in the study group than in the control group(P＜0.05).After treatment,the levels of interleukin 4(IL-4),vascular endothelial growth factor(VEGF),and intercellular adhesion molecule-1(ICAM-1)were significantly lower in both groups than before treatment(P＜0.05),and they were significantly lower in the study group than in the control group(P＜0.05).There was no statistically significant difference in adverse effects between the two groups(P＞0.05).The survival rate of the study group after 1 year of follow-up was significantly higher than that of the control group(P＜0.05).After treatment,the EORTC QLQ-C30 score of the two groups was higher than before treatment(P＜0.05),and the score of the study group was higher than that of the control group(P＜0.05).Conclusions Osimertinib combined with pemetrexed/platinum based chemotherapy regimen is used in the clinical treatment of NSCLC with EGFR and TP53 mutations,which can effectively exert antitumor effects,downgrade the level of inflammation,enhance the efficacy,and improve patient prognosis.And the medication has a high safety and does not significantly increase adverse reactions.
Keywords：Non-small cell lung cancerEGFR combined with TP53 gene mutationPemetrexedCisplatinOsimertinibEfficacyPrognosis
Publication Date：2024-04-20
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 143-147 )